| Q36538285 | AIDS and the lung: update 1995. 1. Pneumocystis carinii pneumonia |
| Q40547099 | AIDS and the lung: update 1995. 3. Intrathoracic Kaposi's sarcoma in patients with AIDS. |
| Q28369142 | Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii |
| Q35557331 | Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal |
| Q34107885 | Antiparasitic agent atovaquone |
| Q57302838 | Antiprotozoal drugs |
| Q33926492 | Central Nervous System Toxoplasmosis in HIV Pathogenesis, Diagnosis, and Therapy |
| Q82029786 | Cerebral toxoplasmosis in AIDS |
| Q28379247 | Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model |
| Q42521070 | Dapsone-induced cholestasis and impairment of bile salt output in the rat. |
| Q40668506 | Diagnosis and Treatment of Toxoplasmosis of the CNS in Patients with AIDS. |
| Q73587644 | Disposition of intravenous 123iodopentamidine in man |
| Q33695186 | Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model |
| Q41331963 | Drug treatment of HIV-related opportunistic infections |
| Q41690799 | Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group |
| Q34393599 | Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis. |
| Q39820806 | Extrapulmonary pneumocystosis. |
| Q92720553 | HIV-Related Cerebral Toxoplasmosis Revisited: Current Concepts and Controversies of an Old Disease |
| Q35535171 | Human antiprotozoal therapy: past, present, and future. |
| Q45751850 | Human immunodeficiency virus infection, Part II. |
| Q39782142 | In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs. |
| Q73097131 | In vitro effects of MOCA and dapsone on rat hepatic and splenic immune cells |
| Q35459188 | Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). |
| Q39143097 | Incidence, immunological and clinical characteristics of reactivation of latent Toxoplasma gondii infection in HIV-infected patients. |
| Q26822988 | Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead |
| Q32061559 | Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. |
| Q34321740 | Medicaid policies for HIV-related prescription drugs. |
| Q38960541 | Neuroepidemiology of HIV infection |
| Q51918844 | Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour. |
| Q35136075 | Penetration of dapsone into pulmonary lining fluid of human immunodeficiency virus type 1-infected patients |
| Q33754929 | Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia |
| Q35114401 | Pharmacokinetics of dapsone in human immunodeficiency virus-infected children |
| Q73030754 | Pneumocystis carinii |
| Q40698523 | Pneumonia in patients with HIV infection. |
| Q35129919 | Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. |
| Q72007727 | Prevention and treatment of Pneumocystis carinii pneumonia in patients infected with HIV |
| Q39558319 | Prevention of infection due to Pneumocystis carinii |
| Q35920640 | Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients |
| Q40977715 | Primary care of the HIV patient: standard practice and new developments in the era of managed care |
| Q39381633 | Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients |
| Q35007043 | Projected survival gains from revising state laws requiring written opt-in consent for HIV testing. |
| Q34195941 | Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus |
| Q48288750 | Prophylaxis of human toxoplasmosis: a systematic review. |
| Q34440857 | Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA |
| Q34482246 | Reactivations of ocular toxoplasmosis after cataract extraction |
| Q38633801 | Recent advances in the neurology of HIV infection |
| Q36318432 | Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy |
| Q58292332 | Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial |
| Q34795033 | Specificity of the Toxoplasma gondii-altered behaviour to definitive versus non-definitive host predation risk |
| Q30425959 | The diagnosis and management of HIV infection |
| Q47986355 | The effect of 2,2'-substitution on the metabolism and toxicity of dapsone in vitro and in vivo. |
| Q40499882 | The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. A review of the literature |
| Q29619501 | The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials |
| Q57121198 | Therapeutic effect of ascorbic acid on dapsone-induced methemoglobinemia in rats |
| Q40434099 | Therapeutic progress IV: Treatment and prophylaxis of Pneumocystis carinii infection |
| Q71011919 | Toxoplasma gondii surface antigen-1 in sera of HIV-infected patients as an indicator of reactivated toxoplasmosis |
| Q41321498 | Treatment regimens for patients with toxoplasmic encephalitis |
| Q37091987 | Usefulness of PCR for detection of Pneumocystis carinii DNA. |
| Q79755656 | [Toxoplasmosis in immunosuppressed patients. Contribution to the knowledge of toxoplasmic infection.]. |
Search more.